Central nervous system (CNS) progression was estimated to be the first site of recurrence in about 33% of cases, independent of disease control elsewhere, in EGFR-mutated NSCLC patients who respond to EGFR-TKI therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.